Mizolastine: Antihistaminic activity from preclinical data to clinical evaluation

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 1, 1999, Pages 3-8

  Simons, F E R ^a  

^a CHILDREN S HOSPITAL RESEARCH INSTITUTE OF MANITOBA   (Canada)

Author keywords

Mizolastine; Pharmacodynamic; Pharmacokinetic

Indexed keywords

ANTIHISTAMINIC AGENT; MIZOLASTINE;

ALLERGIC RHINITIS; ALLERGY; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; URTICARIA;

ADULT; ANIMALS; BENZIMIDAZOLES; HISTAMINE H1 ANTAGONISTS; HUMANS;

EID: 0032967343     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. 1-receptor antagonist drugs. N Engl J Med 1994; 330:1663-70.
2. Simons FER. Antihistamines. In: Middleton E Jr, Reed CE, Ellis EF, et al., eds. Allergy Principles and Practice, 5th edn. St. Louis: Mosby-Year Book, Inc., 1998: 612-37.
3. Synthélabo Groupe. Mizolastine Core Scientific Brochure, Medical and Regulatory Affairs Direction, January 1998.
4. 1-receptor antagonist properties. Eur J Pharmacol 1990; 183:222.
5. 1-receptor antagonist mizolastine in the rodent. Arzneim-Forsch/Drug Res 1995; 45:559-68.
6. Angel I, Pichat P, Arbilla S. Powerful anti-histamine properties of mizolastine in cutaneous oedema in the dog. Allergy 1996; 51 (Suppl. 31):171.
7. Pichat P, Angel I, Arbilla S. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Arzneim-Forsch/Drug Res 1998; 48:173-8.
8. 1-receptor antagonist: lack of sedative potential on the EEG in the rodent. Neuropsychobiol 1995; 32:214-21.
9. Danjou P, Molinier P, Berlin I, Patat A, Rosenzweig P, Morselli PL. Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects. Br J Clin Pharmacol 1992; 34:328-31.
10. Ascalone V, Guinebault P, Rouchouse A. Determination of mizolastine, a new antihistaminic drug, in human plasma by liquid liquid extraction, solid-phase extraction, and column-switching techniques in combination with high-performance liquid chromatography. J Chromatogr 1993; 619:275-84.
11. 1 antihistamine. Ann Allergy 1992; 69:135-9.
12. Pinquier J-L, Caplain H, Cabanis M-J, Dubruc C, Stalla-Bourdillon A, Rosenzweig P. Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine. J Clin Pharmacol 1996; 36:72-8.
13. Mesnil F, Dubruc C, Mentre F, Huet S, Mallet A, Thenot JP. Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling. J Pharmacokinet Biopharm 1997; 25:125-47.
14. Patat A, Gram LF, Dubruc C, Brohier S, Cabanis MJ, Rosenzweig P. Effects of mizolastine, a new antihistamine, on psychomotor performance and memory in elderly subjects. Int Clin Psychopharmacol 1994; 9:101-8.
15. Chosidow O, Dubruc C, Danjou P, et al. Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine. Eur J Clin Pharmacol 1996; 50:327-33.
16. Mesnil F, Mentre F, Dubruc C, Thenot JP, Mallet A. Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the non-parametric maximum likelihood method. J Pharmacokinet Biopharm 1998; 26:133-61.
17. 1-antihistamine, and erythromycin. Clin Pharmacol Ther 1998; 63:214.
18. Bousquet J, Chanal I, Murrieta M, Stalla-Bourdillon A. Lack of subsensitivity to mizolastine over 8-week treatment. Allergy 1996; 51:251-6.
19. Rosenzweig P, Caplain H, Chaufour S, Ulliac N, Cabanis MJ, Thebault JJ. Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol 1995; 40:459-65.